Metreleptin for treating generalised and partial lipodystrophy [ID861]: Notice of Appeal
NICE has received two appeals against the Final Evaluation Determination on the above HST evaluation from the following organisations:
- Lipodystrophy UK
- Aegerion Pharmaceuticals
The appeal panel will convene on Friday 30 August 2019 at NICE, 10 Spring Gardens, London, SW1A 2BU to hear oral representations from the appellants.
Members of the public, including consultees and commentators for this HST evaluation and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are thirty places available for this appeal hearing.
Where possible, requests to attend should be made using the form that will be available on the Institute’s web site https://www.nice.org.uk/event/lipodystrophy-metreleptin-appeal. This form will be available from 22 July 2019 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm on 5 August 2019. Further details relating to public attendance at this appeal are available on the same webpage as above.
A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before 5pm on 5 August 2019. Written requests to attend will also be granted on a first-come, first-served basis.
This page was last updated: